Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hess

Showing results (1181-1190 of 1,218) with videos related to

Pageof 122
Sort By:
Shock (Augusta, Ga.)|October 8, 2010
Challenges to effective research in acute trauma resuscitation: consent and endpointsJohn B Holcomb, Richard Weiskopf, Howard Champion, et al.
Injury|July 6, 2014
Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementationSarah Baraniuk, Barbara C Tilley, Deborah J del Junco, et al.
Immunity|August 14, 2012
Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2Sophie E Acton, Jillian L Astarita, Deepali Malhotra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Transfusion|January 22, 2024
Novel method for determining when a field-collected donor unit is sufficiently fullMark H Yazer, Kendall Werneiwski, Patrick Thompson, et al.
Transfusion|April 1, 2015
Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trialDeborah J Novak, Yu Bai, Rhonda K Cooke, et al.
Annals of Surgery|October 16, 2020
Evidence-Based and Clinically Relevant Outcomes for Hemorrhage Control Trauma TrialsJohn B Holcomb, Ernest E Moore, Jason L Sperry, et al.
Transfusion|December 16, 2017
Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016Jaroslav G Vostal, Paul W Buehler, Monique P Gelderman, et al.
The New England Journal of Medicine|February 19, 2010
Dose of prophylactic platelet transfusions and prevention of hemorrhageSherrill J Slichter, Richard M Kaufman, Susan F Assmann, et al.
Pageof 122

Showing results (1181-1190 of 1,218) with videos related to

Sort By:
Pageof 122
Shock (Augusta, Ga.)|October 8, 2010
Challenges to effective research in acute trauma resuscitation: consent and endpointsJohn B Holcomb, Richard Weiskopf, Howard Champion, et al.
Injury|July 6, 2014
Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementationSarah Baraniuk, Barbara C Tilley, Deborah J del Junco, et al.
Immunity|August 14, 2012
Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2Sophie E Acton, Jillian L Astarita, Deepali Malhotra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Transfusion|January 22, 2024
Novel method for determining when a field-collected donor unit is sufficiently fullMark H Yazer, Kendall Werneiwski, Patrick Thompson, et al.
Transfusion|April 1, 2015
Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trialDeborah J Novak, Yu Bai, Rhonda K Cooke, et al.
Annals of Surgery|October 16, 2020
Evidence-Based and Clinically Relevant Outcomes for Hemorrhage Control Trauma TrialsJohn B Holcomb, Ernest E Moore, Jason L Sperry, et al.
Transfusion|December 16, 2017
Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016Jaroslav G Vostal, Paul W Buehler, Monique P Gelderman, et al.
The New England Journal of Medicine|February 19, 2010
Dose of prophylactic platelet transfusions and prevention of hemorrhageSherrill J Slichter, Richard M Kaufman, Susan F Assmann, et al.
Pageof 122